Enhanced Impact of Psoriasis Severity on the Treatment Demands of Patients During the COVID-19 Pandemic: a Cross-sectional Study Based on a National Psoriasis Registry in China

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Feb 17

PMID 38367975

Authors

Zhihui Yang

Yu Jin

Mingyue Wang

Ruoyu Li

Wen-Qing Li

Hang Li

Affiliations

Soon will be listed here.

Abstract

Objectives: The personalised treatment demands of patients with psoriasis did not get significant attention during the pandemic lockdown. This study aimed to investigate the treatment demands of patients with psoriasis with different severities, stratified by COVID-19 pandemic conditions.

Design: Cross-sectional study design.

Setting: Multicentre study based on a national psoriasis registry in China.

Participants: A total of 22 425 adult patients with psoriasis were enrolled between August 2020 and September 2021.

Primary And Secondary Outcome Measures: The primary outcomes were patient demands for quick healing of skin lesions and improving mental health, which were collected by questionnaires. Multivariable logistic models were used to examine the impact of disease severity, as measured by Psoriasis Area and Severity Index (PASI), body surface area (BSA) and Investigator's Global Assessment (IGA), on treatment demands, as stratified by COVID-19 pandemic conditions (lockdown vs non-lockdown).

Results: Increasing PASI score significantly increased patient demands for rapid healing of skin lesions and improving mental health during non-lockdown periods. The magnitude of both associations further increased during the COVID-19 lockdown from an OR of 1.45 (95% CI 1.27 to 1.65) to 2.19 (95% CI 1.57 to 3.05) and 2.21 (95% CI 2.03 to 2.40) to 2.82 (95% CI 2.24 to 3.55), respectively. The skin lesion healing demand was more triggered by the overall irritation level (measured by IGA, OR 1.64, 95% CI 1.35 to 1.99 during non-lockdown periods vs OR 2.70, 95% CI 1.63 to 4.49 during lockdowns), while the mental health improving demand was more triggered by lesion coverage (measured by BSA, OR 2.01, 95% CI 1.85 to 2.19 vs OR 3.27, 95% CI 2.57 to 4.15).

Conclusions: Psoriasis aggravation significantly increased patients' treatment demands, especially during lockdowns. The used psoriasis severity measures highlighted patients' treatment demands differently. This suggests more accessible and personalised healthcare for patients with psoriasis should be available during future pandemics.

References

Schielein M, Tizek L, Knobloch L, Maassen D, Biedermann T, Zink A . Psoriasis and addiction: assessing mental health based on a cross-sectional study in Germany. Eur J Dermatol. 2021; 31(6):722-729. DOI: 10.1684/ejd.2021.4146. View

Bang C, Yoon J, Chun J, Han J, Park Y, Lee S . Association of Psoriasis With Mental Health Disorders in South Korea. JAMA Dermatol. 2019; 155(6):747-749. PMC: 6506891. DOI: 10.1001/jamadermatol.2019.0315. View

Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E . Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol. 2021; 186(1):59-68. PMC: 8444811. DOI: 10.1111/bjd.20659. View

Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B . Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol. 2011; 132(4):1111-6. PMC: 3366426. DOI: 10.1038/jid.2011.427. View

Langley R, Feldman S, Nyirady J, van de Kerkhof P, Papavassilis C . The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2013; 26(1):23-31. DOI: 10.3109/09546634.2013.865009. View

Abrouk M, Nakamura M, Zhu T, Farahnik B, Koo J, Bhutani T . The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017; 28(6):488-491. DOI: 10.1080/09546634.2016.1278198. View

Mistry S, Ali A, Yadav U, Ghimire S, Hossain M, Shuvo S . Older adults with non-communicable chronic conditions and their health care access amid COVID-19 pandemic in Bangladesh: Findings from a cross-sectional study. PLoS One. 2021; 16(7):e0255534. PMC: 8320993. DOI: 10.1371/journal.pone.0255534. View

Alpsoy E, Polat M, FettahlioGlu-Karaman B, Karadag A, Kartal-Durmazlar P, Yalcin B . Internalized stigma in psoriasis: A multicenter study. J Dermatol. 2017; 44(8):885-891. DOI: 10.1111/1346-8138.13841. View

Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S . Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012; 22(5):663-7. DOI: 10.1684/ejd.2012.1802. View

10.

Thomas L, Azad J, Takwale A . Management of nail psoriasis. Clin Exp Dermatol. 2020; 46(1):3-8. DOI: 10.1111/ced.14314. View

11.

Strober B, Greenberg J, Karki C, Mason M, Guo N, Hur P . Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019; 9(4):e027535. PMC: 6500315. DOI: 10.1136/bmjopen-2018-027535. View

12.

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

13.

Choon S, Lai N, Mohammad N, Nanu N, Tey K, Chew S . Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2013; 53(6):676-84. DOI: 10.1111/ijd.12070. View

14.

Liu L, Lin N, Yu Y, Wang S, Wang J, Cai X . Epidemiology of mental health comorbidity in patients with psoriasis: An analysis of trends from 1986 to 2019. Psychiatry Res. 2023; 321:115078. DOI: 10.1016/j.psychres.2023.115078. View

15.

Singh K, Kondal D, Mohan S, Jaganathan S, Deepa M, Srinivasapura Venkateshmurthy N . Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study. BMC Public Health. 2021; 21(1):685. PMC: 8027966. DOI: 10.1186/s12889-021-10708-w. View

16.

Mahil S, Yates M, Yiu Z, Langan S, Tsakok T, Dand N . Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021; 35(10):e636-e640. PMC: 8447018. DOI: 10.1111/jdv.17450. View

17.

Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E . Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic. Br J Dermatol. 2021; 185(3):671-673. PMC: 8250964. DOI: 10.1111/bjd.20406. View

18.

Lada G, Chinoy H, Talbot P, Warren R, Kleyn C . Impact of the COVID-19 Pandemic on the Mental Health and Quality of Life of Patients with Psoriasis in Tertiary Care; A One-year Follow-up. Acta Derm Venereol. 2022; 102:adv00814. PMC: 9811286. DOI: 10.2340/actadv.v102.2464. View

19.

Takeshita J, Grewal S, Langan S, Mehta N, Ogdie A, Van Voorhees A . Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017; 76(3):377-390. PMC: 5731650. DOI: 10.1016/j.jaad.2016.07.064. View

20.

van de Kerkhof P . Future perspectives on care for patients with psoriasis. What did we learn during the COVID-19. J Dermatolog Treat. 2021; 32(5):477. DOI: 10.1080/09546634.2021.1945655. View